Medical/Pharmaceuticals
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma Report also examines key therapeutic development areas to watch including mRNA, CRISPR, AI-driven drug discovery and more LONDON, Jan. 10, 2022 /...
2022-01-10 16:00
2505
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors. AS...
2022-01-10 08:30
2925
SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE
SINGAPORE, Jan. 7, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has appointed Dr.Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis' technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include dev...
2022-01-07 23:00
3002
Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay
FAIRFIELD, N.J., Jan. 7, 2022 /PRNewswire/ -- Vela Diagnostics announced that itsSentosa® SQ HIV-1 Genotyping Assay is covered for reimbursement from The Centers for Medicare and Medicaid (CMS) startingJanuary 2022. Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare...
2022-01-07 22:00
2361
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from10-13 January 2022. The co...
2022-01-07 21:00
4163
100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
TAIPEI, Jan. 7, 2022 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure i...
2022-01-07 18:53
2001
Li Jian Quan, Chairman of WINNER MEDICAL Co., Ltd., Was Invited to "DIALOGUE PROGRAM" in CCTV-2 (China Central Television)
SHENZHEN, China, Jan. 7, 2022 /PRNewswire/ -- On the evening of January 1, Li Jian quan, chairman of Winner Medical, was a guest on "DIALOGUE PROGRAM" in CCTV-2 (China Central Television) as a representative of entrepreneurs. In the interview, he said that only by insisting on innovation can we b...
2022-01-07 17:47
1659
Elekta to appoint Tobias Hägglöv as Chief Financial Officer
STOCKHOLM, Jan. 7, 2022 /PRNewswire/ -- Elekta (STO: EKTA-B) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. Tobias Hägglöv has previously held the role of CFO at Recipharm as well as senior management posit...
2022-01-07 14:49
1871
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company's latest development. Details are as follows: Morgan Stan...
2022-01-07 08:30
1924
Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
HONG KONG and NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.Alex Zhavoronkov, Founder and Chief Executive Officer of I...
2022-01-07 03:55
2114
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases
SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure has been conducting j...
2022-01-06 22:00
1446
I-Mab Announces Senior Management Team Share Purchase Plan
SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company, includin...
2022-01-06 21:00
3419
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent ...
2022-01-06 20:30
3017
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 6, 2022 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Cadonilimab (PD-1/CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody), the novel immuno-o...
2022-01-06 19:00
2082
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Health Pharmaceutical Limited ("Sino Health") , an affiliated compa...
2022-01-06 14:45
2234
Virtue Diagnostics closes $100 million Series B Funding
SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Virtue Diagnostics, an innovative IVD company, has just announced closingUS$100 million in Series B funding. Virtue Diagnostics, founded in 2019, is focused on clinical tests forChina and emerging markets. SequoiaChina and Morningside Ventures jointly led th...
2022-01-06 11:01
3694
Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th A...
2022-01-06 08:30
6985
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial in the U.S. to...
2022-01-06 01:00
1771
CSafe Global Launches Real-Time Shipment Visibility for Passive Portfolios
CSafe now offers real-time visibility and online ordering for VIP Parcel and Cell & Gene Solutions. DAYTON, Ohio, Jan. 6, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today it has expanded its real-time...
2022-01-06 00:01
2758
Tools4Patient Announces Name Change to Cognivia & Expands Board of Directors
MONT-SAINT-GUIBERT, Belgium, Jan. 5, 2022 /PRNewswire/ -- Cognivia today announced a new name for the company formerly known as Tools4Patient, which provides clinical trials solutions based on AI / ML that account for individual patient personality traits, beliefs and perceptions. The transition ...
2022-01-05 23:00
2139
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2931
